AC Immune Says NLRP3 Inhibitor ACI-19764 Safe And Well Tolerated In Phase 1 With Confirmed CSF Penetration; Initial Cardiovascular Risk Cohort Results Expected By Year End

AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline

AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.

BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

AC Immune Says FDA Grants Fast Track Designation And IND Clearance For Anti-Alpha-Synuclein Immunotherapy ACI-7104 In Early Parkinson's; Phase 2 VacSYn Week-100 Data Expected In H2 2026